Clinical Trials Browser

Phase 2 × NETWORK × Neoplasm, Residual × Clear all

NCT03516279 2026-04-03

Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

Phase 2 Active not recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Chronic-Phase, Neoplasm, Residual

NCT04716075 2025-01-16

ACALLO

Phase 2 Completed

LymphoidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasm, Residual, Lymphoma, Mantle-Cell